Literature DB >> 24923898

Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis.

Mazhar Müslüm Tuna1, Narin Nasıroğlu Imga2, Berçem Ayçiçek Doğan2, Fatma Meriç Yılmaz3, Canan Topçuoğlu3, Gülhan Akbaba4, Dilek Berker2, Serdar Güler5.   

Abstract

INTRODUCTION: Adrenal incidentalomas (AIs) have been associated with an increased incidence of several cardiovascular risk factors. The aim of this study was to investigate plasma adiponectin, leptin, resistin, homocysteine, high sensitive C-reactive protein levels, and carotid intima media thickness (CIMT) in patients with non-functioning AI (NFAI).
MATERIALS AND METHODS: This study included data from 28 patients with NFAI (Group 1) and 41 controls (Group 2). Of the patients, 50 were female and 19 were male, and the mean age was 46.7 (range 37-65) years.
RESULTS: There were no significant differences between Group 1 and 2 in terms of age, sex, or BMI. Hypertension prevalence was significantly higher in the NFAI group than in the control group (p = 0.01). Both groups had similar lipid, blood glucose, homocysteine, uric acid, high-sensitivity CRP levels. Adiponectin, leptin, and resistin levels were similar in both groups. CIMTs were significantly higher in the NFAI group.
CONCLUSION: There is increasing evidence that several cardiometabolic risk factors occur with higher prevalence in non-functioning adrenal incidentaloma patients compared to age-matched healthy subjects. In our study, hypertension prevalence and CIMT were higher in the NFAI group. Serum adipokine levels were similar for both groups.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24923898     DOI: 10.1007/s40618-014-0106-5

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

Review 1.  Investigation protocol: adrenal enlargement.

Authors:  F Mantero; G Arnaldi
Journal:  Clin Endocrinol (Oxf)       Date:  1999-02       Impact factor: 3.478

2.  Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome.

Authors:  M Reincke; J Nieke; G P Krestin; W Saeger; B Allolio; W Winkelmann
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

3.  [Normal value correlates of carotid intima- media thickness and affecting parameters in healthy adults].

Authors:  Fahri Halit Beşir; Sibel Yazgan; Gökhan Celbek; Mesut Aydın; Omer Yazgan; Melih Engin Erkan; Mesut Erbaş; Adem Güngör
Journal:  Anadolu Kardiyol Derg       Date:  2012-05-16

4.  Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience.

Authors:  Abdurrahman Comlekci; Serkan Yener; Senem Ertilav; Mustafa Secil; Baris Akinci; Tevfik Demir; Levent Kebapcilar; Firat Bayraktar; Sena Yesil; Sevinc Eraslan
Journal:  Endocrine       Date:  2009-10-30       Impact factor: 3.633

5.  Adrenal incidentalomas: a manifestation of the metabolic syndrome?

Authors:  M Reincke; M Fassnacht; S Väth; P Mora; B Allolio
Journal:  Endocr Res       Date:  1996-11       Impact factor: 1.720

6.  Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism.

Authors:  Iacopo Chiodini; Valentina Morelli; Antonio Stefano Salcuni; Cristina Eller-Vainicher; Massimo Torlontano; Francesca Coletti; Laura Iorio; Antonello Cuttitta; Angelo Ambrosio; Leonardo Vicentini; Fabio Pellegrini; Massimiliano Copetti; Paolo Beck-Peccoz; Maura Arosio; Bruno Ambrosi; Vincenzo Trischitta; Alfredo Scillitani
Journal:  J Clin Endocrinol Metab       Date:  2010-04-07       Impact factor: 5.958

7.  Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome.

Authors:  G G Garrapa; P Pantanetti; G Arnaldi; F Mantero; E Faloia
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

8.  Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma.

Authors:  Serkan Yener; Sinan Genc; Baris Akinci; Mustafa Secil; Tevfik Demir; Abdurrahman Comlekci; Senem Ertilav; Sena Yesil
Journal:  Endocrine       Date:  2009-03-10       Impact factor: 3.633

9.  Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma.

Authors:  Federica Ermetici; Alexis E Malavazos; Sabrina Corbetta; Lelio Morricone; Chiara Dall'Asta; Massimiliano M Corsi; Bruno Ambrosi
Journal:  Metabolism       Date:  2007-05       Impact factor: 8.694

10.  Hormonal and metabolic evaluation of adrenal incidentalomas.

Authors:  H Wagnerova; D Dudasova; I Lazurova
Journal:  Neoplasma       Date:  2009       Impact factor: 2.575

View more
  15 in total

1.  The presence of nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and severity, and is associated with cortisol levels after dexamethasone suppression test.

Authors:  Mariana Arruda; Emanuela Mello Ribeiro Cavalari; Marcela Pessoa de Paula; Felipe Fernandes Cordeiro de Morais; Guilherme Furtado Bilro; Maria Caroline Alves Coelho; Nathalie Anne de Oliveira E Silva de Morais; Diana Choeri; Aline Moraes; Leonardo Vieira Neto
Journal:  J Hum Hypertens       Date:  2017-11-24       Impact factor: 3.012

2.  Factors affecting operative efficiency and post-operative convalescence in laparoendoscopic single-site (LESS) adrenalectomy.

Authors:  Yao-Chou Tsai; Chung-Hsien Chen; Ya-Hui Hu; Leay-Kiaw Er; Che-Hsiung Wu; Shih-Chieh Chueh; Victor Chia-Hsiang Lin
Journal:  Surg Endosc       Date:  2017-09-15       Impact factor: 4.584

3.  Follow-up of patients with adrenal incidentaloma, in accordance with the European society of endocrinology guidelines: Could we be safe?

Authors:  V Morelli; A Scillitani; M Arosio; I Chiodini
Journal:  J Endocrinol Invest       Date:  2016-10-15       Impact factor: 4.256

4.  Nonfunctioning adrenal incidentaloma affecting central blood pressure and arterial stiffness parameters.

Authors:  Tolga Akkan; Mustafa Altay; Yasemin Ünsal; Murat Dağdeviren; Esin Beyan
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

5.  Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.

Authors:  Marta Araujo-Castro; César Mínguez Ojeda; María Noelia Sánchez Ramírez; Victoria Gómez Dos Santos; Eider Pascual-Corrrales; María Fernández-Argüeso
Journal:  Endocrine       Date:  2022-06-25       Impact factor: 3.925

6.  NEW BIOMARKERS TO PREDICT CARDIOVASCULAR RISK IN PATIENTS WITH ADRENAL INCIDENTALOMA; IRISIN AND NESFATIN-1.

Authors:  M Can; M Kocabaş; M Karaköse; Y Alsancak; F H Yerlikaya; H Caliskan Burgucu; I Cordan; C Kadiyoran; M Kulaksızoğlu; F Karakurt
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Apr-Jun       Impact factor: 1.104

7.  Change of skeletal muscle mass in patients with pheochromocytoma.

Authors:  Seung Hun Lee; Mi Kyung Kwak; Seong Hee Ahn; Hyeonmok Kim; Yoon Young Cho; Sunghwan Suh; Kee-Ho Song; Jung-Min Koh; Jae Hyeon Kim; Beom-Jun Kim
Journal:  J Bone Miner Metab       Date:  2018-09-20       Impact factor: 2.626

8.  "Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study.

Authors:  Diana Lopez; Miguel Angel Luque-Fernandez; Amy Steele; Gail K Adler; Alexander Turchin; Anand Vaidya
Journal:  Ann Intern Med       Date:  2016-08-02       Impact factor: 25.391

9.  Evaluation of Midnight Salivary Cortisol as a Predictor Factor for Common Carotid Arteries Intima Media Thickness in Patients with Clinically Inapparent Adrenal Adenomas.

Authors:  Giuseppe Reimondo; Barbara Allasino; Marcella Coletta; Anna Pia; Giulia Peraga; Barbara Zaggia; Chiara Massaglia; Piero Paccotti; Massimo Terzolo
Journal:  Int J Endocrinol       Date:  2015-05-14       Impact factor: 3.257

10.  Management of adrenal incidentaloma: the role of adrenalectomy may be underestimated.

Authors:  Yun-Lin Ye; Xiao-Xu Yuan; Ming-Kun Chen; Yu-Ping Dai; Zi-Ke Qin; Fu-Fu Zheng
Journal:  BMC Surg       Date:  2016-06-08       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.